NASDAQ:PLSE - Pulse Biosciences Stock Price, Forecast & News

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Pulse Biosciences Inc (NASDAQ:PLSE) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.04. View Pulse Biosciences' Earnings History.

Pulse Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Pulse Biosciences.

1 brokerages have issued 12-month price targets for Pulse Biosciences' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Pulse Biosciences' stock price to reach $6.00 in the next year. This suggests that the stock has a possible downside of 21.2%. View Analyst Price Targets for Pulse Biosciences.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pulse Biosciences.

News headlines about PLSE stock have been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pulse Biosciences earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Pulse Biosciences.

Some companies that are related to Pulse Biosciences include LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO), Alphatec (ATEC), MiMedx Group (MDXG), Utah Medical Products (UTMD), Restoration Robotics (HAIR), Accuray (ARAY), SeaSpine (SPNE) and Iradimed (IRMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Energous (WATT), Advanced Micro Devices (AMD), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), AbbVie (ABBV), Fate Therapeutics (FATE), Portola Pharmaceuticals (PTLA), Roku (ROKU) and Exelixis (EXEL).

(PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

Pulse Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (0.92%), Geode Capital Management LLC (0.75%), Griffin Asset Management Inc. (0.24%), Bank of New York Mellon Corp (0.15%), UBS Group AG (0.07%) and Barclays PLC (0.05%). View Institutional Ownership Trends for Pulse Biosciences.

PLSE stock was sold by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. View Insider Buying and Selling for Pulse Biosciences.

PLSE stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Barclays PLC, Geode Capital Management LLC, Griffin Asset Management Inc., UBS Group AG, Bank of New York Mellon Corp and Citigroup Inc.. View Insider Buying and Selling for Pulse Biosciences.

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PLSE stock can currently be purchased for approximately $7.61.

Pulse Biosciences has a market capitalization of $158.20 million. The company earns $-37,540,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Pulse Biosciences employs 54 workers across the globe.View Additional Information About Pulse Biosciences.

The official website for Pulse Biosciences is http://www.pulsebiosciences.com/.

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]